The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Glioblastoma in England: 2007–2011
Open accessAbstract
AIMS: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumour in adults, with a poor prognosis. Changing treatment paradigms suggest improved outcome, but whole nation data for England is scarce. The aim of this report is to examine the incidence of patients with glioblastoma in England, and to assess the influence of gender, age, geographical region and treatment on outcome. METHODS: A search strategy encompassing all patients coded with GBM and treated from January 2007 to December 2011 was obtained from data linkage between the National Cancer Registration Service and Hospital Episode Statistics for England. RESULTS: There were 10,743 patients coded with GBM in this 5-year period (6451 male, 4292 female), giving an overall national age standardised incidence of 4.64/100,000/year. Incidence increases with age. Median survival overall was 6.1 months. One, 2 and 5-year survivals, were 28.4%, 11.5% and 3.4% respectively. Age stratified median survivals decreased significantly (p<0.0001) with increasing age from 16.2 months for the 20-44 year age group, to 7.9 months for the 45-69 years, and 3.2 months for 70+years. In the maximal treatment subgroup, patients aged up to 69 years had a median survival of 14.9 months. Patients over 60 years were less likely to receive maximal combination treatment but median survival was better with maximal treatment at all ages. CONCLUSIONS: The overall outcome for patients with GBM remains poor. However, aggressive treatment at every age group is associated with extended survival similar to that described in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Cited by
Epidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
Glioblastoma: clinical presentation, diagnosis, and management
McKinnon, C., Nandhabalan, M., Murray, S. A., & Plaha, P. (2021) · BMJ · doi:10.1136/bmj.n1560 · Cited by 391
Tumor-Treating Fields: A Fourth Modality in Cancer Treatment
Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1117 · Cited by 380
Poon, M. T. C., Sudlow, C. L. M., Figueroa, J. D., & Brennan, P. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-68011-4 · Cited by 305
Zhang, C.-X., Zhao, W.-Y., Liu, L., Ju, R.-J., Mu, L.-M., Zhao, Y., Zeng, F., Xie, H.-J., Yan, Y., & Lu, W.-L. (2015) · Oncotarget · doi:10.18632/oncotarget.5354 · Cited by 38
Metadata
- Authors
- Brodbelt, A., Greenberg, D., Winters, T., Williams, M., Vernon, S., & Collins, V. P.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 51
- Issue
- 4
- Pages
- 533-542
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2043702724
- Cited by
- 227
- References
- 2
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glioblastoma in England: 2007–2011. https://app.cochat.ai/papers/10.1016/j.ejca.2014.12.014
- The paper
- Brodbelt, A., Greenberg, D., Winters, T., Williams, M., Vernon, S., & Collins, V. P. (2015). Glioblastoma in England: 2007–2011. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2014.12.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.